Clinically Proven to Improve Perfusion, Accelerate Recovery, and Regenerate Tissue.
CO2Lift® PRO delivers measurable, biopsy-confirmed outcomes across a broad spectrum of clinical indications — from enhanced oxygenation and accelerated post-procedure recovery to structural tissue regeneration and vulvovaginal health.
ENHANCED OXYGENATION & CIRCULATION
CO2Lift® PRO produces quantifiable vascular and perfusion improvements, confirmed across multiple peer-reviewed studies.
+34%
CAPILLARY DENSITY
Increase in capillary density¹
-28%
CAPILLARY DIAMETER
Increase in capillary diameter¹
+3%
ARTERIAL BLOOD FLOW
Increase in arterial blood flow⁵
CLINICAL RESULT: IMMEDIATE INCREASE IN TISSUE OXYGENATION (TCPO₂)
WITH MEASURABLE IMPROVEMENT IN OXYGEN DELIVERY TO TARGET TISSUE.⁵
ALL EFFICACY AND SAFETY CLAIMS ARE SUPPORTED BY PEER-REVIEWED PUBLICATIONS AND CLINICAL STUDY DATA. RESULTS MAY VARY BY INDICATION AND TREATMENT PROTOCOL.
1 LEIBASCHOFF, COLL, ROBERTS. CAPILLARY DENSITY AND DIAMETER OUTCOMES. / SURGICAL TECHNOLOGY INTERNATIONAL.2018; VOL. 32
5 ROMERO DÍAZ, LEIBASCHOFF, MELAMED. TCPO₂, ARTERIAL FLOW, ULCER CLOSURE./ INT J CLIN CASE REPORTS & REVIEWS.2024
FASTER RECOVERY WITH COMBINATION THERAPY
When used adjunctively with energy-based procedures, CO2Lift® PRO significantly shortens downtime and accelerates return to baseline appearance.
RF MICRONEEDLING RECOVERY
Significant reduction in redness, swelling, and irritation within 24 hours of RF microneedling treatment.²
CO₂ RESURFACING RECOVERY
~97% skin recovery by Day 7 following fractionated CO₂ resurfacing, with significantly reduced erythema vs. placebo.³
RETURN TO BASELINE
Faster return to baseline appearance across procedures, supporting improved patient experience and clinical efficiency.⁶
CLINICAL RESULT: ACCELERATED RECOVERY CONFIRMED ADJUNCTIVELY WITH ENERGY-BASED PROCEDURES ACROSS MULTIPLE STUDY DESIGNS.
ALL EFFICACY AND SAFETY CLAIMS ARE SUPPORTED BY PEER-REVIEWED PUBLICATIONS AND CLINICAL STUDY DATA. RESULTS MAY VARY BY INDICATION AND TREATMENT PROTOCOL.
2 MEDRANO, ARRUDA, OZA, SADICK. RECOVERY FOLLOWING RF MICRONEEDLING. / J DRUGS DERMATOL. 2021;20(4):461–465
3 DAYAN, CARVAJAL ET AL. CO₂ RESURFACING RECOVERY AND ERYTHEMA. / J COSMET DERMATOL. 2025
6 WYLES, SHAMBAN. ELASTIN, EPIDERMAL THICKNESS, FIBROBLAST ACTIVITY. / PENDING PUBLICATION (EXPECTED 2026)
CLINICALLY PROVEN SKIN REJUVENATION
Monotherapy data confirms objective improvements in both mechanical skin properties and visible appearance using CO2Lift® PRO alone — without combination procedures.
All efficacy and safety claims are supported by peer-reviewed publications and clinical study data. Results may vary by indication and treatment protocol. 4 Draelos, Shamban. Skin firmness and mechanical properties (monotherapy). / J Cosmet Dermatol. 2023
REGENERATIVE EFFECTS
— HISTOLOGIC EVIDENCE
Biopsy-confirmed data from combination therapy studies reveals deep structural remodeling, not just surface-level improvement. These findings represent some of the most compelling mechanistic evidence for CO2Lift® PRO’s regenerative profile.
Clinical Result: Histologic evidence of tissue regeneration and structural remodeling.
+45.7% RETICULAR ELASTIN
Significant increase in dermal elastin fiber density following treatment.⁶
2X EPIDERMAL THICKNESS
Doubling of epidermal thickness confirmed on biopsy analysis.⁶
FIBROBLAST ACTIVATION
Increased fibroblast activity with new collagen formationand reduction in p21+ senescence cells.⁶
NEOVASCULARIZATION
Biopsy-confirmed epithelial thickening and neovascularization in treated tissue.⁷
REGENERATIVE EFFECTS
— HISTOLOGIC EVIDENCE
Biopsy-confirmed data from combination therapy studies reveals deep structural remodeling, not just surface-level improvement. These findings represent some of the most compelling mechanistic evidence for CO2Lift® PRO’s regenerative profile.
Clinical Result: Histologic evidence of tissue regeneration and structural remodeling.
+45.7% RETICULAR ELASTIN
Significant increase in dermal elastin fiber density following treatment.⁶
2X EPIDERMAL THICKNESS
Doubling of epidermal thickness confirmed on biopsy analysis.⁶
FIBROBLAST ACTIVATION
Increased fibroblast activity with new collagen formationand reduction in p21+ senescence cells.⁶
NEOVASCULARIZATION
Biopsy-confirmed epithelial thickening and neovascularization in treated tissue.⁷
ALL EFFICACY AND SAFETY CLAIMS ARE SUPPORTED BY PEER-REVIEWED PUBLICATIONS AND CLINICAL STUDY DATA. RESULTS MAY VARY BY INDICATION AND TREATMENT PROTOCOL. 6 WYLES, SHAMBAN. ELASTIN, EPIDERMAL THICKNESS, FIBROBLAST ACTIVITY./ PENDING PUBLICATION (EXPECTED 2026) 7 EVANS, LEIBASCHOFF, ALINSOD. VULVOVAGINAL HEALTH, FSFI, DIVA, NEOVASCULARIZATION./ J CLIN RES CASE STUD. 2024
VULVOVAGINAL HEALTH & CO2LIFT® V
CO2Lift® V demonstrates comprehensive, statistically significant improvements across validated functional, structural, and quality-of-life measures in vulvovaginal health.
FSFI & DIVA DOMAINS
Statistically significant improvement across all domains of both the Female Sexual Function Index and DIVA questionnaire.⁷
URINARY FUNCTION & QOL
Improved urinary function and quality of life confirmed via King’s Health Questionnaire.⁷
GENITAL SELF-IMAGE
Improved Female Genital Self-Image Scale scores alongside tissue integrity improvements.⁷
LICHENS
CLEROSUS
Clinical case studies demonstrate improvement in lichen sclerosus and vulvar tissue integrity.⁷
ALL EFFICACY AND SAFETY CLAIMS ARE SUPPORTED BY PEER-REVIEWED PUBLICATIONS AND CLINICAL STUDY DATA. RESULTS MAY VARY BY INDICATION AND TREATMENT PROTOCOL. 7 EVANS, LEIBASCHOFF, ALINSOD. VULVOVAGINAL HEALTH, FSFI, DIVA, NEOVASCULARIZATION./ J CLIN RES CASE STUD. 2024
WOUND HEALING & COMPROMISED TISSUE
CO2Lift® PRO demonstrates robust efficacy in impaired healing andchronic tissue conditions, with outcomes extending well beyond typicalcosmetic endpoints.
100% CLINICAL IMPROVEMENT
All patients demonstrated measurable clinical improvement inwound status.⁸
COMPLETE/ADVANCED HEALING AT 4 WEEKS
Majority of patients achieved complete or advanced healing within 4weeks of treatment.⁸
94.4% SYMPTOM REDUCTION
Reduction in symptom burden by 3 months, with improved granulation and ulcer closure.⁵⁹
ALL EFFICACY AND SAFETY CLAIMS ARE SUPPORTED BY PEER-REVIEWED PUBLICATIONS AND CLINICAL STUDY DATA. RESULTS MAY VARY BY INDICATION AND TREATMENT PROTOCOL. 8 KHIAT, LEIBASCHOFF. WOUND HEALING CLINICAL IMPROVEMENT. / J CLIN RES CASE STUD. 2024
Surgical & Body Applications
REDUCED ECCHYMOSIS
Reduction in bruising and ecchymosis observed following body contouring procedures.¹¹
Photos Courtesy of Dr. Hoyos.
Emerging data supports CO2Lift® PRO’s role in post-surgical recovery and body contouring, with early signals indicating meaningful clinical utility beyond facial indications.
FASTER RECOVERY
CO2Lift® PRO applied Intraoperatively, POD 1 in office, and subsequent 5 days by patient at home.¹¹
Photo courtesy of Dr. Boehm.
ALL EFFICACY AND SAFETY CLAIMS ARE SUPPORTED BY PEER-REVIEWED PUBLICATIONS AND CLINICAL STUDY DATA. RESULTS MAY VARY BY INDICATION AND TREATMENT PROTOCOL. 11 HOYOS, COYOS. POST-SURGICAL BODY APPLICATIONS./ UNPUBLISHED ABSTRACT
SAFETY & MICROBIOME INTEGRITY
Across all published studies, CO2Lift® PRO maintained a consistent safety profile with no adverse events reported and no disruption to the skin microbiome.
ZERO ADVERSE EVENTS
No adverse events reported across studies 2, 3, 4, 5, 7, and 8.
MICROBIOME PRESERVED
No disruption to microbiome diversity confirmed in prospective analysis.¹⁰
BENEFICIAL FLORA INCREASED
Increase in beneficial Cutibacterium species observed post-treatment.¹⁰
Clinical Result: Safe, non-disruptive support for skin and tissue health suitable for sensitive and compromised presentations.
SAFETY & MICROBIOME INTEGRITY
Across all published studies, CO2Lift® PRO maintained a consistent safety profile with no adverse events reported and no disruption to the skin microbiome.
ZERO ADVERSE EVENTS
No adverse events reported across studies 2, 3, 4, 5, 7, and 8.
MICROBIOME PRESERVED
No disruption to microbiome diversity confirmed in prospective analysis.¹⁰
BENEFICIAL FLORA INCREASED
Increase in beneficial Cutibacterium species observed post-treatment.¹⁰
Clinical Result: Safe, non-disruptive support for skin and tissue health suitable for sensitive and compromised presentations.
ALL EFFICACY AND SAFETY CLAIMS ARE SUPPORTED BY PEER-REVIEWED PUBLICATIONS AND CLINICAL STUDY DATA. RESULTS MAY VARY BY INDICATION AND TREATMENT PROTOCOL. 10 HERNANDEZ-ROVIRA, VILLAMARIA, OH, OZARSLAN, WYLES. MICROBIOME INTEGRITY. / J COSMET DERMATOL. 2026
